Joseph Jimenez - Novartis

Joseph Jimenez - Novartis
Total Compensation: $15.7 million

Details: Jimenez is another new face on this year's list, stepping in for Daniel Vasella back in 2010. Last year, Jimenez pulled in a $1.9 million base salary, augmented by $1 million in short-term shares, $10.7 million in long-term shares and the rest in benefits and bonuses.

As Big Pharma faces an ever-deepening patent cliff, Novartis ($NVS), under Jimenez's leadership, has streamlined operations and focused on R&D. The company's job cuts, numbering in the thousands, have mostly been in marketing and administration, allowing the Swiss drugmaker to invest big in drug development to offset the coming generic competition for blockbusters like Diovan. Manufacturing troubles have slowed the company as of late--it reported an 8% earnings decline in first-quarter 2012--but Jimenez is confident that the acquisition of Alcon and the progress of multiple sclerosis treatment Gilenya will get Novartis back on track.

Joseph Jimenez - Novartis

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.